---
title: "Novavax Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287123167.md"
description: "Novavax Inc. (NVAX) shares rose 4.16% to $9.27, outperforming competitors on a positive trading day. The NASDAQ Composite increased by 1.54%, while the Dow Jones rose 1.31%. Despite the gain, NVAX remains 22.56% below its 52-week high of $11.97. Competitors like Johnson & Johnson and Merck saw declines, while Pfizer experienced a slight increase. Trading volume reached 4.9 million, surpassing the 50-day average of 4.3 million."
datetime: "2026-05-20T21:27:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287123167.md)
  - [en](https://longbridge.com/en/news/287123167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287123167.md)
---

# Novavax Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) rose 4.16% to $9.27 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.54% to 26,270.36 and the Dow Jones Industrial Average rising 1.31% to 50,009.35.

The stock's rise snapped a three-day losing streak.

Novavax Inc. closed 22.56% below its 52-week high of $11.97, which the company achieved on February 26th.

The stock outperformed some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 0.30% to $229.32, Pfizer Inc. (PFE) rose 0.51% to $25.79, and Merck & Co. Inc. (MRK) fell 1.09% to $113.00.

Trading volume (4.9 M) eclipsed its 50-day average volume of 4.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 20, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-20-26 1727ET

### Related Stocks

- [NVAX.US](https://longbridge.com/en/quote/NVAX.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [.IXIC.US](https://longbridge.com/en/quote/.IXIC.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)